BRPI0510526A - formulações lìquidas estabilizadas de interferon - Google Patents

formulações lìquidas estabilizadas de interferon

Info

Publication number
BRPI0510526A
BRPI0510526A BRPI0510526-9A BRPI0510526A BRPI0510526A BR PI0510526 A BRPI0510526 A BR PI0510526A BR PI0510526 A BRPI0510526 A BR PI0510526A BR PI0510526 A BRPI0510526 A BR PI0510526A
Authority
BR
Brazil
Prior art keywords
interferon
liquid formulations
stabilized liquid
stabilized
ifn
Prior art date
Application number
BRPI0510526-9A
Other languages
English (en)
Inventor
Fabrizio Samaritani
Alessandra Del Rio
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of BRPI0510526A publication Critical patent/BRPI0510526A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAçõES LìQUIDAS ESTABILIZADAS DE INTERFERON. A presente invenção refere-se a uma composição farmacêutica líquida estabilizada livre de HSA, que compreende um interferon (IFN), sendo que a referida formulação é uma solução que compreende um tampão, um aminoácido e um antioxidante. De preferência o interferon é um IFN-beta recombinante humano.
BRPI0510526-9A 2004-06-01 2005-05-27 formulações lìquidas estabilizadas de interferon BRPI0510526A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04076626 2004-06-01
US61637804P 2004-10-06 2004-10-06
PCT/EP2005/052414 WO2005117949A1 (en) 2004-06-01 2005-05-27 Stabilized interferon liquid formulations

Publications (1)

Publication Number Publication Date
BRPI0510526A true BRPI0510526A (pt) 2007-10-30

Family

ID=34928261

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510526-9A BRPI0510526A (pt) 2004-06-01 2005-05-27 formulações lìquidas estabilizadas de interferon

Country Status (15)

Country Link
US (1) US7731948B2 (pt)
EP (1) EP1750751B1 (pt)
JP (1) JP4988562B2 (pt)
CN (1) CN1993139B (pt)
AU (1) AU2005249233B2 (pt)
BR (1) BRPI0510526A (pt)
CA (1) CA2567310A1 (pt)
EA (1) EA010979B1 (pt)
ES (1) ES2418833T3 (pt)
HK (1) HK1102563A1 (pt)
IL (1) IL179620A (pt)
MX (1) MXPA06014078A (pt)
NO (1) NO20065860L (pt)
UA (1) UA92146C2 (pt)
WO (1) WO2005117949A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1691825T3 (pl) 2003-12-11 2012-02-29 Ares Trading Sa Stabilizowane ciekłe formulacje interferonu
NZ550926A (en) * 2004-05-17 2010-01-29 Ares Trading Sa Hydrogel interferon formulations
EP1800673A3 (en) * 2005-12-23 2007-08-15 Canadian Blood Services Nitrophenyls and related compounds and thimerosal for the inhibition of immune related cell or tissue destruction
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2008066322A1 (en) * 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
CA2692165A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
EP2234645B1 (en) 2007-12-20 2012-05-02 Merck Serono S.A. Peg-interferon-beta formulations
CN105521491B (zh) * 2010-03-01 2020-03-24 西托戴恩有限公司 浓缩蛋白制剂及其用途
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta
US9198955B2 (en) * 2011-03-15 2015-12-01 Biogen Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
RU2527701C1 (ru) * 2013-05-24 2014-09-10 Федеральное государственное бюджетное учреждение "Научный центр реконструктивной и восстановительной хирургии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НЦРВХ" СО РАМН) Способ приготовления средства, обладающего свойством стимуляции регенерации хрящевой, костной, мышечной тканей и способ стимуляции регенерации хрящевой, костной, мышечной тканей с использованием приготовленного средства
AU2015239104B2 (en) 2014-04-04 2018-12-20 Ares Trading S.A. Novel IFN beta protein analogs
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN114053397B (zh) * 2022-01-17 2022-12-20 北京三元基因药业股份有限公司 一种稳定的干扰素多剂量注射液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4469228A (en) 1983-05-31 1984-09-04 Schering Corporation Interferon kit
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IT1244511B (it) 1991-04-15 1994-07-15 Isi Ist Sierovaccinogeno Ital Idrogeli a base di policarbossilati sintetici e proteine per il rilascio controllato di farmaci e procedimento per la loro preparazione.
KR960009385B1 (en) * 1993-11-24 1996-07-18 Samsung Bp Chemicals Co Ltd Apparatus and method for wastewater treatment by activated sludge process type
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5858001A (en) 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
DE69705746T2 (de) 1996-12-20 2001-10-31 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
CA2304808C (en) * 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
AU761577C (en) * 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
SK286654B6 (sk) 1998-04-28 2009-03-05 Laboratoires Serono Sa Spôsob postupného pripájania polyetylénglykolových častí a použitie PEG-polypeptidových konjugátov vyrobených týmto spôsobom
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
JP4944324B2 (ja) 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CA2386228A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
WO2002003430A2 (en) 2000-06-29 2002-01-10 California Institute Of Technology Aerosol process for fabricating discontinuous floating gate microelectronic devices
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
IL156532A0 (en) 2000-12-27 2004-01-04 Ares Trading Sa Lipid microparticles, their preparation and pharmaceutical compositions containing them
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US20040028733A1 (en) 2002-02-08 2004-02-12 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
NZ550926A (en) 2004-05-17 2010-01-29 Ares Trading Sa Hydrogel interferon formulations

Also Published As

Publication number Publication date
WO2005117949A1 (en) 2005-12-15
JP2008500996A (ja) 2008-01-17
US20070292391A1 (en) 2007-12-20
HK1102563A1 (en) 2007-11-30
ES2418833T3 (es) 2013-08-16
NO20065860L (no) 2006-12-19
EA200602257A1 (ru) 2007-04-27
IL179620A (en) 2013-04-30
MXPA06014078A (es) 2007-02-15
EP1750751B1 (en) 2013-04-10
UA92146C2 (ru) 2010-10-11
AU2005249233B2 (en) 2010-10-07
CN1993139A (zh) 2007-07-04
EP1750751A1 (en) 2007-02-14
JP4988562B2 (ja) 2012-08-01
CA2567310A1 (en) 2005-12-15
US7731948B2 (en) 2010-06-08
AU2005249233A1 (en) 2005-12-15
EA010979B1 (ru) 2008-12-30
IL179620A0 (en) 2007-05-15
CN1993139B (zh) 2011-02-16

Similar Documents

Publication Publication Date Title
BRPI0510526A (pt) formulações lìquidas estabilizadas de interferon
BRPI0515118A (pt) conjugados de hormÈnio do crescimento humano com polietileno glicol
EA200501699A1 (ru) Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
AR049635A1 (es) (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
WO2006051103A3 (en) Stable formulations of peptides
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
UA88300C2 (ru) Гидрогелевые композиции, которые содержат интерферон
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
ATE549028T1 (de) Stabile analoga von glp-1
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
HUP0303596A2 (hu) Cinkmentes és cinkben szegény, javított stabilitású inzulinkészítmények
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
DE602005019853D1 (de) Pharmazeutische Zusammensetzung mit lyophilisiertem rekombinantem Faktor VIII ohne Albumin als Stabilisator
NZ593190A (en) Factor viii formulations
BR112022022942A2 (pt) Réplicon de rna que codifica uma proteína spike de coronavírus estabilizada
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
BRPI0720230B8 (pt) formulação nutricional oralmente administrável, uso da formulação, e, composição
EA200600782A1 (ru) Терапевтические применения вариантов хемокинов
DE602007002553D1 (de) Ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
HUP0303309A2 (hu) Csökkentett immunogenitású módosított interferon-alfa
BRPI0401908A (pt) Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2257 DE 08/04/2014.